

for a period of time sufficient for tolerance induction, thereby obtaining a mixture,

- c) introducing the mixture to the individual, and
- d) administering to the individual at least one of drug that is used to modulate the immune response.

144. The method of Claim 143, wherein the drug is chosen from at least one of: methotrexate, rapamycin, cyclosporin, steroid, CD40 pathway inhibitor, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof.

145. A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of at least one of immunoglobulin specific to B7-1 and an effective amount of at least one of immunoglobulin specific to B7-2.

146. The method of Claim 145, further including administering at least one of: calcineurin inhibitor, steroid, and immunosuppressive agent that arrest the growth of immune cells, methotrexate, CD40 pathway inhibitor, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof.

147. The method of Claim 146, wherein at least one of cyclosporin A or FK506 is administered.

148. The method of Claim 146, wherein at least one of methyl prednisone or prednisone is administered.

149. The method of Claim 146, wherein rapamycin is administered.

150. The method of Claim 145, wherein the immunoglobulin specific to B7-1 is administered in an amount between about 1 mg/kg and about 25 mg/kg, and the

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

immunoglobulin specific to B7-2 is administered in an amount between about 1 mg/kg and about 25 mg/kg.

151. The method of Claim 150, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are administered on the day the recipient receives the transplantation.

152. The method of Claim 149, wherein the humanized immunoglobulin specific to B7-1 and the humanized immunoglobulin specific to B7-2 are further administered periodically after the recipient receives the transplantation.

153. The method of Claim 152, wherein the humanized immunoglobulin specific to B7-1 is administered between about 1 mg/kg and about 5 mg/kg, and the humanized immunoglobulin specific to B7-2 is administered between about 1 mg/kg and about 5 mg/kg at least weekly after the recipient receives the transplantation.

154. A method of modulating an immune response of an individual having a transplanted organ, tissue, cell or the like comprising administering an effective amount of the humanized immunoglobulin specific to B7-1, an effective amount of a humanized immunoglobulin specific to B7-2 in a carrier and administering a drug that is used to modulate the immune response of an individual having at least one of a transplanted organ, tissue, or cell, wherein the drug is chosen from at least one of: methotrexate, rapamycin, cyclosporin, steroids, CD40 pathway inhibitor, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof.

155. A method of decreasing an antibody response to an antigen in a mammal, comprising administering to the individual an effective amount of at least one humanized immunoglobulin specific to B7-1 and/or at least one humanized immunoglobulin specific to B7-2, in the presence of the antigen.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

156. The method of Claim 155, further including administering the antigen to the individual.

157. The method of Claim 155, wherein the antigen is chosen from at least one of: tetanus toxoid, Factor VIII, Factor IX, insulin, growth hormone, and a gene delivery vector.

158. A method of treating an individual having a disease comprising:

- a) administering to the individual an effective amount of at least one of immunoglobulin specific to B7-1 and an effective amount of at least one of immunoglobulin specific to B7-2 and
- b) administering to the individual a drug that is used to modulate the immune response.

159. The method of Claim 158, wherein the drug is chosen from at least one of: methotrexate, rapamycin, cyclosporin, steroid, CD40 pathway inhibitor, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof.

160. The method of Claim 158, wherein the disease is chosen from at least one of: an infectious disease, asthma, systemic lupus erythematosus, diabetes mellitus, insulitis, arthritis, inflammatory bowel disease, inflammatory dermatitis, and multiple sclerosis.

## REMARKS

### I. Status of the Claims

Claims 1-142 have been canceled. New claims 143-160 have been added to more particularly point out the subject matter of the invention. All of the new claims find support in the specification as filed.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)